Contrasting Polymorphism of Related Small Molecule Drugs Correlated and Guided by the Computed Crystal Energy Landscape by Braun, DE et al.
Contrasting Polymorphism of Related Small Molecule Drugs
Correlated and Guided by the Computed Crystal Energy Landscape
Doris E. Braun,*,†,‡ Jennifer A. McMahon,§ Lien H. Koztecki,§ Sarah L. Price,†
and Susan M. Reutzel-Edens§
†Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
‡Institute of Pharmacy, University of Innsbruck, Innrain 52c, 6020 Innsbruck, Austria
§Eli Lilly and Company, Indianapolis, Indiana 46285, United States
*S Supporting Information
ABSTRACT: Solid form screening and crystal structure prediction (CSP) calculations were carried out on two related
molecules, 3-(4-(benzo[d]isoxazole-3-yl)piperazin-1-yl)-2,2-dimethylpropanoic acid (B5) and 3-(4-dibenzo[b,f][1,4]oxepin-11-
yl-piperazin-1-yl)-2,2-dimethylpropanoic acid (DB7). Only one anhydrate form was crystallized for B5, whereas multiple solid
forms, including three neat polymorphs, were found for DB7. The crystal structure of B5 is P21/n Z′ = 1 with intramolecular
hydrogen bonding, whereas Forms I and II of DB7 are conformational polymorphs with distinct Z′ = 1 P1̅ structures and
intermolecular hydrogen bonds. A disordered structure for Form III of DB7 is proposed, based on CSP-generated structures
which gave a promising match to the X-ray powder diﬀraction and solid state NMR data for this metastable form. The diﬀerences
in the hydrogen bonding and experimental solid form landscapes of the two molecules appear to arise from the dominance of the
self-assembly of the benzoisoxazolepiperazinyl and dibenzoxepinylpiperazinyl fragments and the consequent inability to produce
amorphous or solvate forms as intermediates for B5. There is a subtle balance between the intramolecular conformational energy
and the intermolecular dispersion, electrostatic and polarization interactions apparent in the analysis of the computationally
generated thermodynamically competitive structures, which makes their relative stability quite sensitive to the computational
method used. The value of simultaneously exploring the computationally and experimentally generated solid form landscapes of
molecules in pharmaceutical development is discussed.
1. INTRODUCTION
Multidisciplinary solid form screening1−3 is routinely con-
ducted in the pharmaceutical and specialty chemicals industries
to ensure that solid forms with the best compromise of physical
and chemical properties are developed. Reports of the late
appearance of polymorphs4,5 and the wide range of methods
that have led to the discovery of novel polymorphs6 show,
however, that there is no standard recipe for comprehensive
experimental solid form screening. With neither a sure ﬁre
approach nor a clear end point to ﬁnding crystal forms, a
computational method for ensuring that all relevant poly-
morphs have been found is highly desirable. To this end,
studies on smaller molecules have established crystal structure
prediction (CSP) as a complement to solid form screening,7−11
helping to rationalize and unify experimental observations on
polymorphs, solvates, and hydrates.12−16 In the most recent
(2010) blind test of CSP methods, the progress toward tackling
larger, ﬂexible molecules allowed a target crystal structure of a
molecule large enough to be seen as a model for modern
smaller drug molecules.17 The success in predicting the crystal
structure of blind test candidate benzyl-(4-(4-methyl-5-(p-
tolylsulfonyl)-1,3-thiazol-2-yl)phenyl)carbamate (XX)18 has led
to a series of studies in which the crystal energy landscapes of
pharmaceuticals, such as olanzapine (LY170053),19 N-[(2R)-
(6-chloro-5-methoxy-1H-indol-3-yl)-propyl]acetamide (mela-
tonin agonist, LY156735),9,10 and 6-[(5-chloro-2-([(4-chloro-
2-ﬂuorophenyl)methyl]oxy)phenyl)methyl]-2-pyridinecarbox-
ylic acid (GSK269984B),20 have been contrasted with industrial
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experimental screening work and used to focus additional
investigations to give an overall picture of each molecule’s
experimental solid form landscape. In this study, we seek to
contrast the crystallization behavior and crystal energy
landscapes of two molecules, which were part of the same
drug discovery program, and show how the solid form
landscape varies with minor chemical modiﬁcations to the
API.21 This shows the extent to which the pharmaceutical
materials tetrahedron,22 the relationships between the possible
structures, properties, performance, and processing, is speciﬁc
to a given API rather than a family, and the potential role of
CSP in providing the required information.
The ﬁrst molecule, 3-(4-(benzo[d]isoxazole-3-yl)piperazin-1-
yl)-2,2-dimethylpropanoic acid (LY2806920, B5, Figure 1a), is
a 5-HT2a agonist that was investigated for the oral treatment of
depression and sleep disorders, while the second, 3-(4-
dibenzo[b,f][1,4]oxepin-11-yl-piperazin-1-yl)-2,2-dimethylpro-
panoic acid (LY2624803, DB7, Figure 1b), is a 5-HT2a agonist
and H1 inverse agonist that was under development as an oral
treatment for both sleep onset and sleep maintenance. Both
molecules are amphoteric, capable of existing in zwitterionic
and charge neutral forms, and have the same hydrogen bonding
groups. Work on screening the two compounds revealed
contrasting solid form behavior, with B5 showing only one
nonsolvated solid form and DB7 crystallizing in at least three
neat polymorphs and multiple hydrates and solvates. Both B5
and DB7 were un-ionized in the observed nonsolvated crystal
forms, but the hydrogen bonding of the common part of the
molecules was diﬀerent. Whereas B5 was intramolecularly
hydrogen bonded in its only solid form, DB7 formed
intermolecular hydrogen bonds in the two readily structurally
characterized anhydrates.
The initial indication of very diﬀerent solid form diversity
between these molecules with a great deal of chemical and
pharmacological similarity led us to calculate the crystal energy
landscapes of the two molecules with the aim of assessing (i)
whether it could account for the diﬀerences in crystallization
behavior, (ii) whether it could propose a structure for DB7
Form III, which had not been structurally characterized by
single crystal diﬀraction for lack of suitable crystals and (iii)
whether the calculations would suggest further experimental
work to characterize the solid form diversity of these molecules.
More generally, the goal of the project was to learn how to
usefully incorporate CSP into an industrial solid form screening
process, given recent extension of the capability for these size
molecules.
2. MATERIALS AND METHODS
2.1. Computational Generation of the Crystal Energy
Landscapes and Lattice Energy Calculations. The CSP search23
for low energy structures of the two neutral molecules was based on
separately calculating the intermolecular lattice energy, Uinter, and the
intramolecular energy penalty, ΔEintra, for changing the conformation
of the molecule. The static lattice energy of a crystal, Elatt = Uinter +
ΔEintra, is calculated from increasingly accurate estimates of ΔEintra,
based on electronic structure calculations on the molecules, and
improving the quality of the atom−atom model for the intermolecular
forces for Uinter. The plausible range of conformational ﬂexibility for
molecules B5 and DB7 which needed to be covered in the
CrystalPredictor search (Figure 1) was established by potential energy
surface scans and analyses of the Cambridge Structural Database24
(Supporting Information section 1). These showed that three ﬂexible
CrystalPredictor25−27 searches were appropriate, corresponding to
three diﬀerent carboxylic acid conformations with either ϕ4 = 180°
(for intermolecular hydrogen bonds) or ϕ4 = 0° giving an
intramolecular hydrogen bond, with two diﬀerent regions (iA and iB
searches, Figure 2). The other dimethylpropanoic acid angles (ϕ1−ϕ3)
were included as search variables, and ϕ5 was ﬁxed to 50.9° for B5 and
47.0° for DB7. Each CrystalPredictor search covered Z′ = 1 structures
in 14 of the most common space groups (P1, P1̅, P21, P21/c, P21212,
P212121, Pna21, Pca21, Pbca, Pbcn, C2/c, Cc, C2, and P21/m),
generating 1 150 000 plausible crystal structures for B5 and
2 000 000 for DB7. The intermolecular electrostatic interactions
Figure 1. (a, b) The related molecules being studied, with atomic
numbering. The abbreviated names B5 and DB7 refer to the diﬀerent
size and identity of rings comprising the benzoisoxazole and
dibenzoxepinyl ring systems. The highly ﬂexible intramolecular
degrees of freedom that were explicitly varied in the CrystalPredictor
search procedure are in green (ϕ1: C9−N3−C12−C13, ϕ2: N3−
C12−C13−C14, ϕ3: C12−C13−C14−O3, ϕ4: C13−C14−O3−H1,
with B5 numbering, corresponding angles used for DB7), with gray
showing the additional angles that were also included in the ﬁnal
CrystalOptimizer reﬁnement.
Figure 2. Minimum energy of conformations of B5 with an
intramolecular hydrogen bond (ϕ4 = 0°) within the iA and iB search
regions. The conformations of the acid−piperazine fragments in
Figure S5 (Supporting Information) are equal in energy, but the
addition of the benzoisoxazole fragment leads to the minimum in the
iB region being ∼1 kJ mol−1 more stable. For DB7, the corresponding
minima with the dibenzoxazepine fragment diﬀer by ∼3.7 kJ mol−1,
with iA being more stable (both PBE0/6-31G(d,p) isolated molecule
estimates).
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were initially calculated from atomic charges, but in a subsequent
reﬁnement of the CrystalPredictor structures using the DMAﬂex-
Quick28 and DMACRYS29 algorithms, they were calculated from
distributed multipoles30 derived from analysis of the PBE0/6-
31G(d,p) molecular wave function. All other intermolecular energy
terms are represented by the FIT empirical exp-6 repulsion-dispersion
potential.29,31 The more stable crystal structures were then reﬁned
allowing all of the conformational degrees of freedom depicted in
Figure 1, the cell parameters and the molecular positions and
orientations to be optimized using the CrystalOptimizer database
method,27 which eﬃciently uses the calculated ΔEintra and distributed
multipoles from the many PBE0/6-31G(d,p) molecular wave function
calculations.
Polarization of the molecular charge density within the crystal was
investigated by using the polarizable continuum model (PCM)32 as
implemented in Gaussian03. The PCM lattice energies were calculated
from the conformational energy and distributed multipoles calculated
at the PBE0/6-31G (d,p) level, in a polarizable continuum with ε = 3
(a value typical for organic crystals32−34), and the same FIT repulsion-
dispersion potential.29,31 Furthermore, Helmholtz free energies35
derived from the elastic constants36 and k = 0 phonons37 calculated
in the rigid-body harmonic approximation were estimated for the most
stable structures (∼200 for each molecule) at 298 K. This approximate
Helmholtz free energy surface calculated using the polarizable
continuum model to approximate the induction contribution is
referred to as the “Crystal Energy” and is reported in section 3.3, with
the relative energies for selected structures at the intermediate stages
given in section 3.4.3.
More computationally demanding calculations based on diﬀerent
models for the lattice energy were used to further investigate the
sensitivity of the crystal energies to the theoretical method. PIXEL
calculations38−40 estimate the repulsive (ER), dispersion (ED),
electrostatic (Coulombic, EC), and polarization (also called induction,
EP) contributions to the intermolecular lattice energy, and the
contributions from individual pairs of molecules within a crystal are
estimated from the charge density for the crystal constructed from the
MP2/6-31G(d,p) ab initio charge density of the isolated molecule.
Periodic electronic structure calculations were also carried out with the
CASTEP plane wave code41 using the Perdew−Burke−Ernzerhof
(PBE) generalized gradient approximation (GGA) exchange-correla-
tion density functional42 and ultrasoft pseudopotentials,43 with the
addition of a semiempirical dispersion correction (Tkatchenko and
Scheﬄer,44 TS). To see the eﬀect of changing the dispersion
correction, additional single point calculations, using the DFT-TS
optimized structures with the addition of the Grimme06 (G06)45
dispersion correction instead, were performed.
The computationally generated low energy structures were
compared using the Crystal Packing Similarity Module in Mercury46
to determine the root-mean-square deviation of the non-hydrogen
atoms in a cluster of n molecules (rmsdn) and the XPac program to
examine the supramolecular constructs (SCs).47
2.2. Materials and Solid Form Screening Experiments. B5
Form I (purity 99.9%) and DB7 Form II (purity 99.6%) were obtained
from Lilly Research Laboratories.
The solvent crystallization screens of the two compounds
encompassed evaporative crystallization at diﬀerent temperatures (5,
25, and 50 °C), cooling crystallization (varying the cooling rate),
crystallization by standard and reverse antisolvent addition, crystal-
lization by vapor diﬀusion, crystallization by pH swing using the B5
hydrochloride and DB7 phosphate salts, slurry equilibration, and cross
seeding. Over 30 solvents and mixtures thereof, purchased from
diﬀerent suppliers, were used. All solvents used for crystallization
screening were reagent grade (99+% purity). Furthermore, hot-stage
microscopic investigations and diﬀerential scanning calorimetry
thermocycling were attempted. In total, more than 300 crystallization
experiments were performed per compound in the tailored screens
whose crystallization conditions and outcomes are reported in the
Supporting Information, section 8 (B5) and section 11 (DB7).
Table 1. Crystallographic Data for B5 Form I and DB7 Forms I and II
phase designator B5 Form I DB7 Form I DB7 Form II
empirical formula C16H21N3O3 C22H25N3O3 C22H25N3O3
formula weight 303.36 379.45 379.45
temperature/K 100(2) 100(2) 100(2)
wavelength/Å 1.54178 1.54178 1.54178
crystal size/mm 0.20 × 0.10 × 0.05 0.20 × 0.05 × 0.05 0.10 × 0.10 × 0.05
crystal system monoclinic triclinic triclinic
space group P21/n P1̅ P1 ̅
a/Å 14.0905(3) 9.3970(3) 9.2754(4)
b/Å 6.2506(1) 10.8925(3) 10.0504(5)
c/Å 17.0170(3) 11.0095(4) 11.8580(6)
α/° 90 65.728(2) 106.010(4)
β/° 91.321(1) 67.321(2) 108.236(3)
γ/° 90 77.584(2) 99.895(3)
volume/Å3 1498.36(5) 945.71(5) 967.99(8)
Z 4 2 2
density (calculated)/ g cm−3 1.345 1.333 1.303
theta range for data collection/° 4.03−64.91 4.46−65.13 4.77−64.94
index ranges −15 ≤ h ≤ 16 −11 ≤ k ≤11 −10 ≤ h ≤ 10
−6 ≤ k ≤ 7 −12 ≤ k ≤ 12 −11 ≤ h ≤ 11
−16 ≤ l ≤ 19 −11 ≤ l ≤ 12 −13 ≤ l ≤ 13
no. of measured, independent and observed [I > 2σ(I)] reﬂections 8498/2357/2061 6835/2812/2282 9170/3130/2529
reﬁnement method full-matrix least-squares on F2
data/parameters/restraints 2357/206/1 2812/260/1 3130/259/0
goodness-of-ﬁt 1.10 (on F2) 1.05 (on F2) 1.03 (on F2)
ﬁnal R indices [I > 2σ(I)] R1 = 0.0402 R1 = 0.0438 R1 = 0.0392
wR2 = 0.1061 wR2 = 0.1128 wR2 = 0.1049
R indices (all data) R1 = 0.0454 R1 = 0.0537 R1 = 0.0490
wR2 = 0.1103 wR2 = 0.1212 wR2 = 0.1115
largest diﬀ peak and hole 0.16 and −0.18 e·Å−3 0.24 and −0.25 e·Å−3 0.22 and −0.23 e·Å−3
Crystal Growth & Design Article
dx.doi.org/10.1021/cg500185h | Cryst. Growth Des. 2014, 14, 2056−20722058
The anhydrate polymorphs of DB7 were named in consecutive
order of appearance, that is, ﬁrst polymorph Form I, second Form II,
etc. Scaling up the screening results led to the following methods for
the best phase pure samples used in the subsequent characterization.
DB7 Form I was prepared by dissolving 1 g of DB7 in 65 mL of
anisole at 90 °C. To complete dissolution, 2 mL of tetrahydrofuran
was added. The solution was ﬁltered, cooled to 5 °C, and seeded with
Form I seeds (which had been prepared by fast evaporation of DB7
from methyl-t-butyl-ether at 50 °C). Heptane (75 mL) chilled to 5 °C
was dripped in slowly until precipitation began. The solid product was
isolated by vacuum ﬁltration and air-dried at room temperature (RT).
DB7 Form II was prepared by dissolving 200 mg of DB7 in 25 mL of
methyl isobutyl ketone with light heating. The solution was cooled to
RT and seeded with Form II (which had been prepared by slow
evaporation of DB7 from ethyl acetate at 5 °C). The solid product was
isolated by vacuum ﬁltration and air-dried at RT. DB7 Form III was
produced by dehydrating the dihydrate (Hy2) in a 0% relative
humidity (RH) (P2O5) chamber at RT overnight. Hy2 (280 mg) was
prepared by dissolving amorphous DB7 (prepared by rotovapping a
dichloromethane solution of the compound) with stirring in 10 mL of
water at RT. Within 15 min, a thick white slurry had formed. The solid
product was isolated by vacuum ﬁltration and dried initially in a 75%
RH chamber and then at ambient RH.
In contrast, the vast majority of the crystallization experiments on
B5 gave the same phase-pure neat Form I (Supporting Information
section 8). Single crystals were grown by slow evaporation of an
acetone solution of B5.
2.3. Single Crystal X-ray Diﬀractometry. Single crystal X-ray
diﬀraction data for B5 Form I and DB7 Forms I and II were collected
using a Cu Kα radiation source (λ = 1.54178 Å) and a Bruker D8-
based 3-circle geometry diﬀractometer equipped with a SMART APEX
II 6000 CCD area detector. Cell reﬁnement and data reduction were
accomplished using the SAINT software program.48 The structures
were solved by direct methods using the program package WinGX49
(SIR200450 and SHELXL9751). Non-hydrogen atoms were reﬁned
anisotropically. All hydrogen atoms bonded to carbon atoms were
generated by a riding model on idealized geometries with Uiso(H) =
1.5Ueq(C) for −CH3 groups and Uiso(H) = 1.2Ueq(C) for all other
hydrogen atoms. The polar hydrogens were identiﬁed from the
diﬀerence map and reﬁned isotropically, with the exception of H1 in
B5 Form I and DB7 Form I, where the positions were reﬁned with a
constrained O−H bond distance. For further details, see Table 1.
2.4. Thermal Analysis. Diﬀerential scanning calorimetry (DSC)
was conducted using a TA Q1000 DSC. Samples were equilibrated at
22 °C in hermetically sealed aluminum pans and heated to 180−250
°C at 1, 5, 10, or 50 °C min−1 with a 50 mL min−1 nitrogen purge. The
temperature and heat ﬂow were calibrated against indium melting. The
stated errors on the given temperatures (extrapolated transition onset
temperatures) and enthalpy values are 95% conﬁdence intervals
(minimum three measurements).
2.5. Determination of Solubility. In an attempt to quantitatively
measure the free energy diﬀerence between DB7 Forms I and II as a
function of temperature, kinetic solubility measurements were made
for the two polymorphs in methyl isobutyl ketone (MIBK) over a
range of temperatures using Crystal16 parallel reactors.
2.6. Solid-State NMR Spectroscopy. Cross-polarization/magic
angle spinning (CP/MAS) NMR (SSNMR) spectra were obtained on
a Bruker Avance III 400 wide-bore NMR spectrometer operating at
1H, 13C, and 15N frequencies of 400.131, 100.623, and 40.546 MHz,
respectively, and using Bruker 4 mm triple and double resonance
probes. The MAS rate was set to 10 kHz ± 2 Hz using a Bruker MAS-
II controller. 1H decoupling was achieved using the SPINAL6452
decoupling sequence at a proton nutation frequency of 100 kHz for
13C and 50 kHz for 15N. Spinning sidebands were suppressed using a
ﬁve-pulse total sideband suppression (TOSS) sequence.53 For
acquisition of 13C spectra, a 3.4 ms linear RF power ramp
(RAMP100 shaped CP pulse) was used for cross-polarization from
1H to 13C.54 The acquisition time was set to 34 ms and spectra were
acquired over a spectral width of 30 kHz with a recycle delay of 5 s
(B5) or 7 s (DB7). The 13C chemical shifts were externally referenced
(±0.05 ppm) to the proton-decoupled 13C peak of neat (liquid)
tetramethylsilane via the high-ﬁeld resonance of adamantane (δ = 29.5
Figure 3. Preparation and transition pathways of the B5 and DB7 solid forms at diﬀerent temperatures and relative humidities (RH). I, II, and III −
anhydrous forms, Hy2 − dihydrate, HyA − hydrate A, S − isostructural solvates from methanol, ethanol, and 2-propanol. Superscript “o” indicates
the thermodynamically stable anhydrate form. EV − solvent evaporation, (r)AA − (reverse) antisolvent addition, VD − vapor diﬀusion, CC −
cooling crystallization and TC − temperature cycling experiments.
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ppm). 15N CP/MAS NMR acquisition parameters were as follows: 90°
proton RF pulse width 2.9 μs, contact time 0.5 (short) or 3.0 (normal)
ms, pulse repetition time 60 s, MAS frequency 10 kHz, spectral width
22 kHz, and acquisition time 46 ms. 15N chemical shifts were
externally referenced to liquid nitromethane via the 15N peak of α-
glycine (δ = −349.5 ppm). Nonquaternary suppression experiments
used to remove signals of rigid methine and methylene carbons were
conducted using a 50 μs preacquisition delay. Unless speciﬁed
otherwise, the sample temperature was regulated to 25 °C to minimize
frictional heating caused by sample spinning. Low-temperature MAS
experiments were conducted using a Bruker BCU-Xtreme temperature
controller.
3. RESULTS
3.1. Crystallization Results − The Solid Form Diversity
of B5 and DB7. The experimental screen for solid forms
resulted in one anhydrate form for B5 (Supporting Information
section 8). However, some additional XRPD peaks from
products of selected crystallization experiments indicated the
possibility of one or more transient phases, present as minor
impurities (Tables S13 and S18 of the Supporting Informa-
tion).
The possibility of using an amorphous DB7 phase, which was
considerably more soluble than the DB7 crystalline forms, gave
more options in its solid form screen, in terms of vapor
diﬀusion onto solids and slurry crystallizations (Table S26 of
the Supporting Information). Three anhydrous forms, two
hydrates (a stoichiometric dihydrate (Hy2), and a hydrate
(HyA) containing 1.25−1.95 mol of water per mole DB7),
three isostructural solvates from methanol (SMeOH), ethanol
(SEtOH), and 2-propanol (S2‑PrOH), and the amorphous phase
emerged from the DB7 solid form screen. Desolvation studies
allowed us to further expand the diversity in solid form screen
space for DB7, providing the only route to Form III.
Samples of the neat forms suitable for structural character-
ization by single crystal X-ray diﬀraction could be obtained for
B5 Form I and DB7 Forms I and II, but not Form III, the
dehydration product of DB7 Hy2. The work to propose a
structural model for Form III is presented in section 3.3.2.
SSNMR (section 12.4 of the Supporting Information) shows
that the piperazine N3 of DB7 is protonated in the two
hydrates, in contrast to the anhydrate forms. A follow-up
investigation55 of the zwitterionic hydrates (c.f. piroxicam,56
norﬂoxacin57) and their transformations shows how the
interactions of DB7 with water complicate the solid-state
behavior of DB7.
A summary of the solid forms of B5 and DB7 and their
conversion pathways is given in Figure 3.
3.2. Crystal Structures. 3.2.1. B5: Form I. B5 crystallizes in
the monoclinic space group P21/n, with Z′ = 1. The B5
molecule adopts a conformation with the carboxylic acid
forming an intramolecular hydrogen bond with the piperazine
nitrogen N3, which is similar to the most stable conformation
of the isolated molecule, with a rmsd1 of 0.28 Å with
conformation iA (Figure 2). Layers of B5 molecules are
formed by translation of B5 along the a and b axes. Adjacent
layers are either related by inversion, where the N2 piperazine
nitrogen is involved in a weak C−H···N intermolecular
interaction forming close packed centrosymmetric B5 dimers
or by 21 symmetry (Figure 4).
3.2.2. DB7: Forms I and II. DB7 crystallizes in the triclinic
space group P1 ̅ with Z′ = 1 in both Forms I and II, but the
dimethylpropanoic acid side chain of the DB7 molecule adopts
distinct conformations in the two anhydrate polymorphs
(Figure 5). Both structures are quite close to local minima
(ϕ4 = 180°) in conformational energy of the isolated molecule:
Form I being very close (rmsd1 = 0.15 Å), and Form II (rmsd1
= 0.60 Å) diﬀering from a local minimum structure mainly in
the orientation of the carboxylic acid group (ϕ3). Both DB7
crystal structures have a single, strong intermolecular hydrogen
bonding interaction, though to diﬀerent acceptors, in contrast
to the intramolecular hydrogen bond in B5. In DB7 Form I, the
O3−H···N1 interaction between the carboxylic acid and the
oxepine N links DB7 molecules into chains which propagate
along the a direction (Figure 6b). In DB7 Form II, the O3−
H···N3 interaction between the carboxylic acid and the
piperazine N links DB7 molecules into centrosymmetrically
related dimers (Figure 6d). In each of the two structures, the
DB7 molecules form layers involving the strong O3−H···N
hydrogen bonds and C−H···π and π···π interactions to the
dibenzoxepinyl ring (Figure 6b,d). Adjacent layers are related
by inversion (Figure 6a,c).
3.3. Crystal Energy Landscapes. The most stable
calculated structures on the crystal energy landscapes of both
B5 (Figure 7a) and DB7 (Figure 7b) correspond to the only
(B5, Form I) and most stable (DB7, Form II) experimental
structures, respectively. The second structurally characterized
DB7 anhydrate, Form I, is found as a higher energy structure
but is one of the densest generated. Thus, the crystal energy
landscapes are suﬃciently realistic to reproduce the known
crystal structures well (Figure 8) and make it worthwhile to
examine the alternative plausible crystal packings of B5 and
DB7 (Figure 7) over a range of low energy and high density
structures. The energy gap between the global minimum and
the second lowest energy structure is bigger for B5 than DB7
(1.4 kJ mol−1 vs 0.2 kJ mol−1), suggestive of a more complex
Figure 4. Packing diagram of B5 viewed along the b axis. The
symmetry elements relating the adjacent B5 layers are shown.
Figure 5. Overlay of DB7 conformations in experimentally observed
Forms I (red) and II (blue).
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solid-state for DB7, although these energy gaps are smaller than
the uncertainty in our calculations.
The two crystal energy landscapes diﬀer substantially in
packing eﬃciency, with the low energy B5 structures generally
falling in the packing index range of 70−74% and the lowest
energy DB7 structures being in the 66−70% range. Hence,
while the low energy structures of both molecules are within
the expected range of packing coeﬃcients for organic
molecules, the B5 structures are at the high end and DB7 at
the low end of the plausible density spectrum. The calculations
thus show that the sterically more demanding dibenzoxepinyl
substituent of DB7 cannot pack as eﬃciently as the planar
benzoisoxazole in B5. The packing of the two piperazinyl
substituted ring systems is contrasted in section 3.3.1c.
Although a wide range of conformations are low in energy
for B5 and DB7 in isolation (section 1 of the Supporting
Information) and so were considered in the search, only a
limited number of distinct conformers are able to pack in the
low energy minima on the crystal energy landscape (Figure 7,
section 3.3.1a). The diﬀerent carboxylic acid conformations
favor intermolecular hydrogen bonding as in DB7 Forms I and
II and intramolecular hydrogen bonding as in B5. Although
counterintuitive, the majority of the calculated low energy B5
structures contain the intramolecular hydrogen bond, while
most of the low energy DB7 structures are intermolecularly
hydrogen bonded, many involving R2
2(12) dimers hydrogen
bonding the carboxylic acid to the piperazine N3. The
hydrogen bonding diversity is analyzed in more depth in
section 3.3.1b.
Thus, the crystal energy landscapes show that thermody-
namic advantage accounts for the diﬀerent hydrogen bonding,
conformations, and crystal packing observed in the most stable
forms of B5 and DB7. Their further use as a complement to
solid form screening is to ascertain whether there could be
other structures that are likely to be polymorphs and thus see
whether the experimental screening appears to have yielded the
practically important polymorphs. The appearance of poly-
morphs reﬂects the balance between kinetic and thermody-
namic eﬀects, and even in the case of B5, the energy preference
for the known form is too small to conﬁdently predict
monomorphism. Whether the alternative structures are likely to
be polymorphs depends on the structural relationships between
the hypothetical low energy structures and the known
polymorphs,58,59 which might indicate whether it is likely that
they could nucleate separately and exist as distinct free energy
minima at ﬁnite temperatures. Hence, the next stage is to
compare and contrast the more favorable structures labeled in
Figure 7 and establish which hypothetical structures warrant
careful consideration as potential polymorphs. This analysis is
used to propose a structure for DB7 Form III (section 3.3.2).
The experimental information on the relative stability of
polymorphs is contrasted with the analysis of the sensitivity of
the relative energies to the computational model used (section
3.4.3; Table S3 of the Supporting Information).
3.3.1. Structural Diversity on the Crystal Energy Land-
scapes. (a). Conformational Diversity. Despite the range of
conformations covered in the searches, it is notable that only six
conformations (nine if the position of the carboxylic acid
proton is taken into account) are found among the lowest
energy and most densely packed structures for both molecules,
and these diﬀer according to the aromatic substituent. For B5,
only four conformations (ignoring proton positions) are able to
pack (very) densely (Figure 9). The two intramolecularly
hydrogen bonded conformers iA and iB found in the majority
of the low energy structures are very close to the conforma-
tional minima in Figure 2, with rmsd1 values of less than 0.5 Å
and ΔEintra of less than 10 kJ mol−1. The other conformations
seen in the low energy B5 structures are intermolecularly
hydrogen bonded structures (eA and eD, Figure 9).
Figure 6. Packing and hydrogen bonding motifs present in DB7 Forms I (a, b) and II (c, d). Hydrogen bonds shown as green dotted lines; hydrogen
atoms were omitted in (a) and (c) for clarity.
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Five distinct conformations can be found among the most
stable and most dense calculated DB7 structures (Figures 7b
and 9), three of which are similar to the four B5 conformations.
Thus, only conformers eB and eC are observed exclusively for
DB7, with the most stable eB structure being Form II, eC
giving a structure with a particularly low energy for its low
density, and eC′ giving Form I.
(b). Hydrogen Bonding Motifs. Although both molecules
have three nitrogen and three oxygen atoms as potential
hydrogen bond acceptors, only the intramolecularly hydrogen
bonded (Figure 9) and six intermolecularly hydrogen bonded
graph-set motifs (Figure 10) are found in the computer
generated structures in Figure 7, and each conformation is
associated with a particular hydrogen bond acceptor (Figure 9).
The variety of hydrogen bonding motifs is even more restricted
within the Z′ = 1 structures which are explicitly labeled in
Figure 7: intramolecular hydrogen bonds and the R2
2(12)
intermolecular motif can be found for both molecules, and DB7
also has as favorable motifs the observed C1
1(11) and
experimentally unobserved C1
1(6) chains.
(c). Contrasting Packing of the Benzoisoxazolepiperazin-
yl/Dibenzoxepinylpiperazinyl Moieties. The program XPac47
was used to compare the diﬀerent crystal packings of the
Figure 7. Lowest crystal energy structures for (a) B5 and (b) DB7
generated in CSP searches (PCM + FE results), with the experimental
structures encircled. Structures are classiﬁed according to hydrogen
bonding graph set motifs. The structures used in the analysis and
deﬁned in Tables S4 and S5 of the Supporting Information are labeled
by their rank on generation by CrystalPredictor and in the text are also
labeled by conformation; for example, B5-iA11 corresponds to the
only observed B5 structure. The structures in .res format are available
from the authors on request.
Figure 8. Overlay of the experimental (colored by element) and
computed crystal structures (green) of (a) B5 Form I, rmsd15 = 0.32 Å,
(b) DB7 Form I, rmsd15 = 0.22 Å, and (c) DB7 Form II, rmsd15 = 0.25
Å.
Figure 9. B5 and DB7 conformations and graph-set motifs observed
among the most favorable (energy and density, labeled in Figure 7)
calculated structures. i − intramolecularly hydrogen bonded, e −
intermolecularly hydrogen bonded, conformations marked with (′)
diﬀer only by a 180° rotation of COOH. The hydrogen bond donor
(light-blue dot) and acceptor groups (open circle) that are used in the
most favorable structures of a given conformation are marked for the
intermolecularly hydrogen bonded structures. ΔEintra (kJ mol−1) gives
the range of conformational energies with respect to the global
conformational B5 or DB7 minimum calculated at PBE0/6-31G(d,p)
using PCM (ε = 3).
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benzoisoxazolepiperazinyl or dibenzoxepinylpiperazinyl (aro-
matic-piperazinyl hereafter) moiety in the labeled structures
(Figure 11) to complement the hydrogen bond analysis.
Remarkably, there is 3D similarity between some structures,
implying that they have comparable packing of the aromatic-
piperazinyl moiety, and yet the diﬀerent arrangement of the
acid group (section 4.1 of the Supporting Information) can
change the hydrogen bonding from inter- to intramolecular.
However, it is also notable that B5 and DB7 have many
structures that have at most a 1D similarity with another
structure, including a moderately high energy structure B5-iA2,
which has a unique packing arrangement.
For each molecule, it is possible to estimate the
intermolecular binding energy within the 2D supramolecular
constructs, that is, the average binding energy of the molecules
within the layers. The B5-AB2 layer observed in the
experimental structure is, according to the PIXEL pairwise
estimates (Figure 12), particularly strongly bound. This B5-
AB2 layer is also seen in the low energy structures B5-iA7 and
B5-iA1095, and so their close relationship to the experimental
Figure 10. Intermolecular hydrogen bonding motifs observed in the computationally generated B5 and DB7 structures (Figure 7). In bold and
underlined are those in labeled structures. Experimentally observed motifs are indicated with an asterisk (*).
Figure 11. 2D and 3D structural relationships between computationally generated low-energy (a) B5, illustrated in Figure 12, and (b) DB7
structures, illustrated in Figure 13, based on the non-hydrogen atoms of the benzoisoxazolepiperazinyl/dibenzoxepinylpiperazinyl fragments and
medium XPac cutoﬀ parameters (δang = 10°, δtor and δdhd = 14°, VdW search radius of 1.5 Å). Numbers correspond to hypothetical crystal structures,
with the experimental ones highlighted in yellow. Structures exhibiting 3D similarity are within purple outlined boxes, two-dimensional
supramolecular constructs (2D SCs) are the connection points (e.g., AB1), with the letters reﬂecting similarities. All B5-ABx structures are double
layers composed of the same 2D layer AB (Figure 12), and DB7-2GG1 is a double layer of DB7-GG1.
Crystal Growth & Design Article
dx.doi.org/10.1021/cg500185h | Cryst. Growth Des. 2014, 14, 2056−20722063
form suggests that these structures would have to be trapped in
the alternative stackings of this layer, that diﬀer only in weak
van der Waals contacts, to be observable polymorphs. The
strongest 2D construct is B5-CC1, but this layer does not stack
well as the structures in which this is found, B5-iA13 and B5-
iA19, have less favorable lattice energies (Table S10 of the
Supporting Information) than the experimental structure.
The two strongest 2D constructs of DB7 are present in the
experimental forms, DB7-2GG160 in Forms I and III (section
3.3.2), and DB7-EE2 in Form II (i.e., the most stable layers lead
to stable packings). The relationship between the observed
structures is shown by the computer-generated structure DB7-
eB498 having 3D packing similarity in the aromatic-piperazinyl
moiety to Form I and III, but the Form II eB propanoic acid
side chain conformation.
(d). Overall Similarity in Crystal Structures B5 and DB7.
The comparison of 19 low energy high density structures on
the B5 landscape, and 25 on the DB7 landscape, clearly shows
Figure 12. Illustration of the packing similarities of common building blocks (Figure 11a) in labeled structures on the B5 crystal energy landscape
(Figure 7a). Note that B5-A, B5-B, and B5-C are 1D SCs, and all others are 2D. The range of energies of each supramolecular construct has been
derived from the PIXEL pairwise molecule-molecule energies in Tables S6 and S8 of the Supporting Information.
Figure 13. Illustration of the packing similarities of common building blocks (Figure 11b) in the labeled structures on the DB7 crystal energy
landscape (Figure 7b). The range of energies of each supramolecular construct has been derived from the PIXEL pairwise molecule-molecule
energies in Tables S7 and S9 of the Supporting Information.
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that there is much more structural diversity for DB7 (Figure
11) with many more unique 2D packings of the dibenzox-
epinylpiperazinyl fragment of DB7, and many more B5
structures having the same layers of the benzoisoxazole-
piperazinyl fragments. The aromatic-piperazinyl packing,
conformations (Figure 9), and hydrogen bonding motifs
(Figure 10) in the low energy and higher density structures
on the crystal energy landscapes (labeled in Figure 7) in
relation to the observed structures is important in determining
the likelihood that the hypothetical structures could be
kinetically trapped as metastable polymorphs, and this is
discussed in light of the relative stability of the structures, as
determined in 3.4.3. However, ﬁrst we need to establish the
structure of DB7 Form III.
3.3.2. Proposed DB7 Form III Structure(s). Form III is a high
energy polymorph, obtained exclusively by dehydrating DB7
Hy2. As a dehydration product, high quality single crystals
suitable for X-ray structure analysis could not be obtained.
Short contact time solid-state 15N NMR spectroscopy experi-
ments conﬁrmed that DB7 was in the neutral form, and the 1:1
correlation between the number of peaks in the solid-state
13C/15N NMR spectra and the number of carbon/nitrogen
atoms in DB7 established that the structure was Z′ = 1 though
there were a couple of notable diﬀerences that are discussed
later. Therefore, XRPD and the computationally generated
crystal energy landscape (Figure 7b) should be capable of
deriving the structure of Form III. The experimental Form III
diﬀraction pattern was indexed to a triclinic unit cell (at −173
°C: a = 9.620 Å, b = 10.405 Å, c = 12.206 Å, α = 74.50°, β =
80.74°, γ = 69.13°; at 25 °C: a = 9.510 Å, b = 10.223 Å, c =
12.032 Å, α = 75.01°, β = 81.36°, γ = 68.96°) using the ﬁrst 20
peaks with DICVOL04 on statistical assessment of systematic
absences,61 as implemented in the DASH structure solution
package.62 This was compared with the simulated XRPD
patterns for all of the structures in Figure 7b. Three of the
simulated patterns (all P1̅, Z′ = 1 structures) showed a
promising match (Figure 14a), with structures DB7-iA63, DB7-
iB214, and DB7-eB2422 all having the same (3D) packing of
the dibenzoxepinylpiperazinyl fragments. Two structures, DB7-
iA63 and DB7-iB214, diﬀer in only the conformation of the
dimethylpropanoic acid (Figure 14b). The third structure,
DB7-eB2422, diﬀers in conformation and in being an
intermolecularly hydrogen bonded structure and was elimi-
nated as a possible structure for Form III by the worse XRPD
match (Figure 14) and the absence of any distinct band in the
region of intermolecularly hydrogen bonded νN−H) vibrations
(above 3020 cm−1).
The decay of diﬀraction intensity in the experimental Form
III XRPD pattern and the fact that the computationally
generated structures DB7-iA63 and DB7-iB214 show isostruc-
tural packings, diﬀering only in the orientation of the
dimethylpropanoic acid group, indicate that the Form III
structure may be disordered. This assumption is backed-up by
solid-state 13C NMR spectra of DB7 Form III, which
consistently show a clear splitting of the peaks for just the
methylene and methyl carbons of the dimethylpropanoic acid
side-chain (Figure 15). It is also consistent with no peak
splitting being observed by solid-state 15N NMR spectroscopy
(Figure S21, Supporting Information). As shown in Figure 15,
aside from the comparatively less intense 13C resonances of the
aromatic carbons at −50 °C, there appears to be little diﬀerence
between the SSNMR spectra collected at 25 and −50 °C,
eliminating dynamic disorder as the ratio between the split peak
intensities, which is not 50:50, does not change.
Figure 14. (a) Experimental DB7 Form III powder X-ray diﬀraction pattern obtained at room temperature and −173 °C (top and second)
compared with the closest matching simulated patterns for the computationally generated structures (DB7-iA63, DB7-iB214, and DB7-eB2422) and
a hybrid structure DB7-ABIII constructed from DB7-iA63 and DB7-iB214. (b) Superimposed asymmetric units of structure DB7-ABIII, showing the
two diﬀerent conformers proposed to account for site disorder in Form III.
Figure 15. 13C CP/MAS NMR spectra of DB7 Form III at −50 °C
(top) and 25 °C (bottom). Peak splitting marked with arrows.
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To test the disorder assumption, we constructed a hypo-
thetical P1 Z′ = 2 structure comprising the two conformers
present in DB7-iA63 and DB7-iB214. The structure was lattice
energy minimized using both the method used to generate the
crystal energy landscape (Figure 7b) and by DFT-D (Table S3
of the Supporting Information). The program PLATON63
showed that the resulting lattice energy minimum (DB7-ABIII
hereafter, Figure 14b) can be described as a P1 ̅ Z′ = 1 structure
with a 50% occupancy of the two sites for C18 and C21 (Figure
1). DB7-ABIII also gave a powder X-ray diﬀraction pattern that
was a reasonable match to that of Form III (Figure 14), as did
the powder patterns with variable occupancy ratios, although
there was some variation in the intensity of some peaks
(Supporting Information section 6 and Figure S12). The
striking similarities between the structures, simulated powder
X-ray diﬀraction patterns and simulated solid-state 13C NMR
spectra (Supporting Information section 12.2) of DB7-iA63,
DB7-iB214, and DB7-ABIII strongly suggest that structures with
disorder variation in the conformation would provide a
reasonable match to the experimental data on Form III.
Thus, a range of disordered structures varying between DB7-
iA63, DB7-ABIII, and DB7-iB214 is consistent with the DB7
Form III being a phase-pure disordered structure.
The ordered structure DB7-iA63 is more stable than DB7-
iB214 and DB7-ABIII, suggesting that more molecules should be
in the iA conformation; that is, DB7-iA63 should form the
major component if the disorder is being stabilized by
conﬁgurational entropy.64 However, as Form III is prepared
by dehydrating Hy2, which contains the iB conformation, it is
more likely that the disorder arises from an inability of all
molecules to change conformation during the dehydration
process. Desolvation (dehydration) has often been shown to
lead to metastable higher energy forms (e.g., cinacalcet HCl65),
featuring molecules trapped either in a high energy
conformation or high energy packing. It is diﬃcult to estimate
the energy barrier to ﬂip from iA to iB within a condensed
phase. Hence, the disorder ratio in Form III is likely to depend
on the experimental transition conditions. This is consistent
with the observation that across all of the Form III materials we
have generated to date, we were able to see a range of 13C
NMR peak intensity ratios, but we were never able to produce a
perfectly ordered Form III sample nor were we able to “ﬂip” the
major and minor componentsthat is, the same conformation
was always the major species. Thus, we conclude that DB7
Form III has disorder in the side chain and is based on the
structures DB7-iA63 and DB7-iB214, with the ratio of
conformations depending on how the sample is prepared.
Forms I and III are closely related (Figure 11); both
polymorphs contain the layer DB7-2GG1 but with diﬀerent
conformations of the acid group. For a conversion to occur in
the solid-state, the iA and iB molecules in Form III must change
conformation so that the intramolecular hydrogen bonds in
Form III become intermolecular in Form I. The observation
that Form III transforms easily to Form I conﬁrms that the
rearrangement of the acid group, despite involving changes in
hydrogen bonding, is relatively facile.
There is a considerable diﬀerence between metastable Forms
I and III and the stable Form II, both in conformation,
hydrogen bonding, and the packing of the aromatic-piperazinyl
moiety. Thus, the transformations (Figure 3) to the most stable
polymorph involve considerable rearrangement (Figure 9)
consistent with Form I and III being kinetically stabilized
metastable polymorphs.
3.4. Thermodynamic Stability of DB7 Anhydrous
Forms. 3.4.1. Thermal Measurements/Semischematic En-
ergy Temperature Diagram. The three anhydrate polymorphs
of DB7 were examined with DSC (Figure 16a). The DSC
curves of Forms I and II show only the melting of each of the
two forms: melting for Form I occurs at 176.0 ± 0.3 °C (onset
temperature) with an enthalpy of fusion of ΔfusHI = 43.4 ± 0.3
kJ mol−1, and melting of Form II is observed at 180.9 ± 0.1 °C
with an enthalpy of fusion of ΔfusHII = 48.3 ± 0.2 kJ mol−1.
Since Form II melts at a higher temperature and exhibits a
higher enthalpy of fusion than Form I, it can be concluded from
Figure 16. (a) DSC curves of DB7 polymorphs (heating rate 1 or 10 °C min−1). Inset shows the Form III to Form II phase transformation. (b)
Semischematic energy/temperature diagram of DB7 polymorphs (I - blue, II - red, and III - green). m.p.: melting point, G: Gibbs free energy, H:
enthalpy, ΔfusH: enthalpy of fusion, ΔtrsH: transition enthalpy, liq: liquid phase (melt). The bold vertical arrows mark the experimentally measured
enthalpies.
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the heat of fusion rule66 that the two forms are monotropically
related. Upon slowly heating Form III (heating rate of 1 °C
min−1), an exothermic phase transformation to Form II with an
onset temperature at 95.9 ± 0.1 °C and an enthalpy of
transition (ΔtrsHIII−II) of −13.3 ± 0.2 kJ mol−1 occurs. Traces
of Form I may also be present after the solid-state
transformation. By applying faster heating rates (>5 °C
min−1), the melting point of Form III was observed between
118 and 121 °C, followed by a recrystallization process, the
melting of Form I, another recrystallization process, and ﬁnally
the melting of Form II. The melt of Form III produced by fast
heating crystallizes mainly as Form II with some Form I, in
marked contrast to the diﬃculty of nucleating Form I or Form
II from any melt of Form I or Form II (Figure S19 of the
Supporting Information). To test the hypothesis that seed
crystals of Form I/II could have been present to induce
crystallization with heating, DSC experiments were conducted
for Form III spiked with either 3% Form I or Form II. Spiking
did not appear to change the outcome. Furthermore, spiking
the cooled melt of DB7 with Forms I or II and heating the
mixtures did not lead to recrystallization, suggesting that Form
III may have templated the crystallization of the more stable
polymorphs.
A monotropic stability relationship66 between Forms I and
III and Forms II and III was established by the observation of
Form III melting near 120 °C and the lower enthalpy of fusion
ΔfusHIII = 35.3 ± 0.4 kJ mol−1 (calculated by applying Hess’
law: ΔfusHIII = ΔfusHII + ΔtrsHIII−II). Hence, the thermodynamic
relationship of the three forms of DB7, shown in a
semischematic energy temperature diagram (Figure 16b), has
no transition points; that is, none of the free energy curves
intersect below the melting point. Collectively, the rank order
of stability of the DB7 polymorphs at all temperatures (below
melting) is Form II > Form I≫ Form III. A phase pure sample
of Form I, kept in a glass vial under ambient conditions, did not
transform to the stable Form II within the 18 months of the
investigation, indicating that the kinetic stability of Form I is
high. In contrast, samples of Form III, kept under the same
conditions as Form I, completely transformed to mixtures of
Forms I and II.
3.4.2. Solubility Experiments. Form I was conﬁrmed to be
more soluble (less stable) than Form II between 30 and 60 °C
in methyl isobutyl ketone, and kinetic solubility data plotted in
van’t Hoﬀ form, allowing for extrapolation to higher and lower
temperatures, showed no signs of convergence, let alone
crossover (section 12.3 of the Supporting Information). These
data support the DSC interpretation of a monotropic stability
relationship between Forms I and II, with Form II being
thermodynamically more stable at all temperatures. More
quantitative stability diﬀerences could in principle be obtained
from equilibrium solubility measurements,12 but the equili-
brium solubility of Form I could not be determined, as all but
one measurement in ethanol, methyl ethyl ketone, acetonitrile,
and methyl isobutyl ketone at 20, 30, 40, and 50 °C showed at
least partial conversion of Form I to Form II. These results
nonetheless conﬁrm that Form II is the thermodynamically
stable polymorph, at least in the temperature range of greatest
importance in pharmaceutical development.
3.4.3. Relative Lattice Energy Diﬀerences. The experimen-
tal DSC data suggest that the lattice energies relative to Form II
of DB7 should be approximately 4.9 ± 0.8 kJ mol−1 for Form I
and 13.3 ± 0.2 kJ mol−1 for Form III, making the common but
questionable assumption that the heat capacities and zero-point
energies are the same for all polymorphs.12,67 This, and the
relative stability of DB7 Form II and the only known structure
of B5 relative to a representative sample of the computer
Figure 17. Relative lattice energies of the most stable computationally generated (a) B5 and (b) DB7 structures calculated using diﬀerent methods:
CryOpt − CrystalOptimizer, PCM − isolated molecule relaxed structures with average polarization from the PCM model, PCM + FE − crystal
energy using PCM with the addition of rigid-body free energies, PIXEL + ΔEintraPCM − PIXEL Uinter energies with the addition of PCM ΔEintra, DFT-
D, periodic density functional theory relaxations with dispersion correction (TS or G06). Tie lines have been added to highlight the changes in
relative ordering. Structures with same hydrogen bonding motif/conformations (Figures 9 and 10) have the same color. Each background color
indicates that the structure was that obtained by optimization by the ﬁrst method and kept ﬁxed for re-evaluation within the following methods.
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generated structures, can be used to assess diﬀerent methods of
estimating the crystal energies (Figure 17 and section 5 of the
Supporting Information).
Assuming that the conformational energy penalty and
molecular charge distribution were the same as in the isolated
molecule gives the CryOpt structures in Figure 17 in which the
conformation was allowed to change due to the packing forces.
Approximating the crystal environment by a polarizable
continuum33 in the calculation of ΔEintra and the distributed
multipoles and reoptimizing the lattice with the molecule held
rigid (Figure 7, PCM in Figure 17) stabilizes most of the
intermolecularly hydrogen bonded crystal structures (eA, eB,
etc.) relative to structures where the hydrogen bond is
intramolecular (iA or iB). However, using the PIXEL estimate
of the intermolecular lattice energy with the polarization, as
well as all other terms estimated by integration over the isolated
molecule ab initio charge density and the PCM intramolecular
energy penalty, markedly destabilizes the intermolecularly
hydrogen bonded structures for B5. Although the PIXEL
model evaluates the intermolecular energy, particularly the
polarization, in a more crystal and molecule speciﬁc way, the
inability to optimize the crystal structures with this energy
model will aﬀect the relative energies as they are very sensitive
to the crystal structure.68 Complete optimization of these
crystal structures with a periodic electronic structure method
(DFT-D(TS)) leads to signiﬁcant rerankings relative to the
lattice energy methods based on molecular electron density
calculations, expanding the energy range particularly for B5.
These periodic methods should provide a better optimization
of the molecular conformation and crystal packing and treat all
inter- and intramolecular forces in the same way. Furthermore,
proton migration from the neutral to the zwitterionic state may
be possible during the optimization, although it only occurred
for one hypothetical structure, B5-eA2117 (Table S10,
Supporting Information). However, the calculations are
extremely expensive, even using a functional that gives a
signiﬁcantly worse description of the molecular charge
distribution than was used for the single molecule charge
densities. The periodic electronic structure methods require an
empirical correction for the dispersion energy, and re-evaluating
the periodic ab initio energy with a diﬀerent dispersion
correction (DFT-D(G06)) provides a signiﬁcant reranking and
expansion of the energy range for DB7, changing the most
stable structure from a likely component of Form III to the
correct structure Form II (Figure 17).
B5 and DB7 are particularly demanding of methods of
evaluating the lattice energy because of the range of
conformations, types of hydrogen bonding and predominantly
dispersion bound close contacts, including many π···π and C−
H···π interactions that give a total lattice energy within a small
energy window. PIXEL evaluations of the diﬀerent contribu-
tions between pairs of molecules within the crystal structures
(Tables S6−S9 of the Supporting Information) show that the
dispersion generally is the most important contribution to
lattice stability, usually greater than the electrostatic contribu-
tion, but often smaller than the combined electrostatic and
polarization contributions. For example, pairs of stacked
intramolecularly hydrogen bonded B5 molecules have a similar
energy from the dispersion interaction to pairs of molecules
connected by intermolecular hydrogen bonds.
For both molecules, the R2
2(12) intermolecular interaction
(Figure 10) is the most stable pairwise interaction (ignoring
ΔEintra) as it involves both hydrogen bonding and dispersion
stabilization. The other intermolecularly hydrogen bonded
pairwise interactions are of the same magnitude as pairs of
intramolecularly hydrogen bonded molecules (section 5.1 of
the Supporting Information), emphasizing that we cannot
assume that hydrogen bonding predetermines the crystalliza-
tion behavior of B5 or DB7.
The DFT-D models were relatively successful in calculating
reasonable energy diﬀerences between DB7 Forms I and II
(+2.61 kJ mol−1 and +3.55 kJ mol−1 using the TS and G06
dispersion corrections respectively, in comparison to the
experimental ΔtrsHII−I = 4.9 ± 0.8 kJ mol−1 from the diﬀerence
of ΔfusH). The other methods gave an unrealistic energy
diﬀerence of over 10 kJ mol−1 (Figure 17).
The relative stability of crystal structures should be
determined by the Gibbs free energy, rather than the lattice
energy, although the observed monotropic relationship
between the polymorphs implies the same ranking. A crude
estimate of the diﬀerential free energy from the eﬀect of
harmonic rigid-molecule motions within the lattice does cause
signiﬁcant reranking (contrast PCM and PCM + FE in Figure
17), showing that the neglect of thermal eﬀects is another
uncertainty in the relative energies. Given that the theoretical
basis for these methods have diﬀerent strengths and weaknesses
for the diﬀerent contributions to the crystal energy, we can only
conclude that the observed form of B5 and Form II DB7 are
the most stable forms (consistent with experiment) within the
errors of the currently available computer models.
4. DISCUSSION
4.1. Diﬀerent Crystallization Behavior of B5 and DB7.
The close structural relationship between B5 and DB7,
including the same hydrogen bonding functionality, might
have been expected to lead to related solid forms. However, B5
readily crystallizes but in only one structure (Figure 3) with
intramolecular hydrogen bonding (Figure 4), whereas DB7
forms three polymorphs, an amorphous form and a variety of
hydrates and solvates (Figure 3). The two ordered DB7
polymorphs, I and II, have intermolecular hydrogen bonds, yet
Form III appears to have intramolecular hydrogen bonds. The
unexpected diﬀerence in the hydrogen bonding is explained by
the calculations, which suggest that the structures of B5 Form I
and DB7 Form II are the most stable (Figure 17) with the
diﬀerence in substituents aﬀecting the packing eﬃciency and
hence the balance of the dispersion and hydrogen-bonding
interactions. The crystal energy landscape of DB7 was used to
ﬁnd structures which gave reasonable matches to the XRPD
pattern of Form III and to propose a structure, which is likely
to be disordered, helping to characterize this form. Hence, this
study has illustrated both of the anticipated uses of a CSP
studyconﬁrming that the most stable structure has been
found and helping determine the structures of polymorphs by
ﬁnding which best match powder patterns and SSNMR spectra.
However, it has also illustrated the challenge of such
applications for molecules such as DB7: the computational
energy ranking is not yet suﬃciently reliable when the
structures are so close in energy, and the disorder resulted in
more than one generated structure providing a match to the
powder diﬀraction (Figure 14) and SSNMR data (Figure S24
of the Supporting Information) of Form III.
Experimental screening is not a wholly automated process:
the discovery of the metastable forms of DB7 relied in part on
the formation of amorphous and solvated forms, which could
not be similarly produced for B5 (section 8.9 of the Supporting
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Information). Establishing the relationships between the
diﬀerent solid forms of DB7 required tailored experimentation,
though this eﬀort was focused by the simultaneous analysis of
the experimental data and the crystal energy landscape. Since
the calculations only generate structures that are thermody-
namically plausible and the barely understood kinetics of
crystallization determines which of them may be observed,58
the crystal energy landscapes can only currently be used to
understand the occurrence of metastable polymorphs and to
rationalize complex crystallization behavior in conjunction with
solid form screening. Thus, it is the complementarity aﬀorded
by packing analysis of structures calculated to be thermody-
namically plausible69 and the full elaboration of the
experimental solid form landscape that, when conducted
simultaneously, allows a comprehensive picture of the
crystallization possibilities to emerge.
4.2. Do We Expect to Find More Polymorphs? The
analysis of the similarities and diﬀerences in the more likely
(lower energy) CSP generated structures is an extension of the
skills being adopted by scientists in understanding their
experimental crystal forms47,70−72 to larger collections of
structures. However, interpreting whether the relationships
imply that the unobserved structures may be metastable
polymorphs, components of disorder, or could never crystallize
needs the experience of this type of study.58
Provided that a reasonable packing (within the packing index
range ∼65−75%) is achievable, a molecule may be expected to
exist in at least one stable crystal structure: realizing potential
metastable polymorphs from the crystal energy landscape
(Figure 7), on the other hand, will depend on there being a
route to selectively form or possibly trap them. For DB7, the
conformational energy barriers estimated for an isolated
molecule are quite large, in particular, for ϕ1, ϕ2, and ϕ5
(Figure 1), but the PCM calculations suggest that they would
be signiﬁcantly moderated by the environment. Such estimates
are challenging as concerted minor adjustments of multiple
torsion angles can produce the transformation between
conformation iA and iB (Figure 2) more readily than a 180°
rotation of the dibenzoxepinyl ring (ϕ5), which is implausible in
a condensed phase. Certainly, the diﬀerent conformations in
the observed forms and their transformations suggest that the
barriers to rearrangement of the molecules can be overcome in
solution, in the melt and sometimes even in the solid state. This
makes it diﬃcult to judge whether the other plausible generated
structures could be kinetically trapped as metastable poly-
morphs.58 Although the ease of conformational change in dilute
solutions will be very similar for both molecules, the kinetics of
conformational change may well diﬀer in the supersaturated
solutions encountered in the crystallization process. Fast
crystallization into the more densely packed B5 structures
may restrict conformational rearrangement, whereas the poorer
packing and disorder in Form III, which is prepared from Hy2,
shows that conformational rearrangement can occur within the
condensed phases of DB7.
B5 can close pack with itself remarkably well in the most
stable structure, with a conformation very close to the most
stable in isolation (Figure 2). This is perhaps surprising for such
a complex molecular shape but has also been observed for
another model pharmaceutical GSK269984B.20 Both form only
one anhydrous form and crystallize easily in the lowest energy
structure. There are other B5 structures that are within the
energy range of polymorphism; however, the two that are
probably the most thermodynamically competitive, B5-iA1095
and B5-iA7, share the same highly stable 2D construct B5-AB2
with the observed form. The fact that B5-iA11 (Form I) was
observed in all crystallization experiments (section 8 of the
Supporting Information) implies that B5-iA1095 or B5-iA7 may
not be trapped as distinct structures during crystallization. The
most thermodynamically plausible potential metastable poly-
morph of B5 is B5-eA1247, as this has one of the most
distinctive packing arrangements, featuring the R2
2(12) dimer
seen in DB7 Form II. Attempts to seed the crystallization of B5
with DB7 Form II did not yield a novel polymorph from
solution (Table S27 of the Supporting Information). The fast
crystallization kinetics of B5 Form I and the diﬃculty of
avoiding seeding with this form probably account for the
observed (or apparent) monomorphism of B5.
In contrast, DB7 has no good way of packing with itself to
give a dense structure. By forming intermolecular hydrogen
bonds, it can produce stable structures but with a lower packing
eﬃciency than B5. It seems likely that this accounts for the
propensity of DB7 to form solvates. The CSP generated
structures in Figure 7 do not have voids large enough to
accommodate solvent molecules, in contrast to the behavior of
the frameworks of inclusion compounds,73 but this may reﬂect
a low barrier to collapsing to a neat form. Certainly, the
crystallization behavior of DB7 (Figure 3) is linked to the
formation of solvates/hydrates, though there is no close
relationship between the characterized zwitterionic hydrates
and the lower energy unobserved structures. This is not
surprising, as diﬀerent proton positions and hence hydrogen
bonding directionality usually produce diﬀerent low energy
structures.8,74,75 Proton positions usually have a major eﬀect on
relative energies of otherwise similar structures, though some
hydrates provide exceptions leading to disorder.8,76 The
structural diversity on the crystal energy landscape of DB7
may also account for the ease of forming an amorphous
phase.77 The ability to ﬁnd solvates and use amorphous input
material meant that a wider range of crystallization conditions
could be explored for DB7 than B5 and led to the discovery of
Form III. The diversity of structures means that we cannot
exclude even more neat forms being found for DB7, but the
relative energy calculations (Figure 17) suggest that these are
likely to be as metastable as Forms I and III. We have probably
found the most practically important polymorphs because the
observed forms feature the most stable layers and diverse
packings. Thus, this study is suﬃcient to provide reassurance
that the most stable neat forms of B5 and DB7 are known, and
if either were to be progressed in development, further seeking
of polymorphs would not appear to be warranted. However,
further work on the hydrates of DB7 would be necessary, as
described in a forthcoming paper.55
4.3. Value of Calculations and Readiness for Use in
Solid Form Screening. Solid form screening is an essential
step toward ensuring that suitable solid-state forms are
incorporated by design into quality drug products. Given this
and other recent successes in predicting crystal structures of
molecules approaching the complexity of typical modern
pharmaceuticals,10,18−29 CSP appears to be poised to
signiﬁcantly enhance pharmaceutical development by providing
a reassurance of having found all practically important
polymorphs (i.e., the one to be incorporated in the drug
product and those whose formation needs to be avoided by the
design of the crystallization process). In this study, the
calculation of the crystal energy landscapes and consideration
of possible conformations of moderately complex, but
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structurally related B5 and DB7, were suﬃciently accurate to
rule out there being signiﬁcantly more stable and less soluble
undiscovered neat polymorphs, where “signiﬁcant” is on the
scale of the solubility, stability, and conformational diﬀerence of
ritonavir,78 at least with respect to Z′ = 1 structures in the 14
most common space groups. However, the methods currently
available were not able to reliably calculate the relative lattice
energies of DB7 Forms I−III, let alone their free energy
diﬀerences. In fact, accurately predicting the stability order of
polymorphs of even small organic molecules such as
methylparaben79 at temperatures relevant to drug processing
and storage remains a challenge for developing computational
methods.80,81
A major diﬃculty with using CSP to augment industrial solid
form screening is the computational expense in terms of
resources and time currently required to generate a crystal
energy landscape. The time that it takes to complete the
calculations is typically longer than that allotted during drug
development to select a ﬁnal crystal form and is further
increased with the use of diﬀerent methods of assessing the
relative energies, the number of structures that need to be
carefully evaluated, and the need to calculate properties, such as
SSNMR spectra. All of these factors depend on the energy gaps
and range of structures for the speciﬁc molecule,82 which will
only be apparent once a reasonable approximation to the crystal
energy landscape has been calculated.
The computational cost of our study is consistent with the
suggestion20 that CSP studies would be most obviously
worthwhile for compounds in late-stage development, which
is well after most solid form landscapes are typically explored
experimentally. In this scenario, the value of a calculated crystal
energy landscape will not only be to reaﬃrm that the practically
important polymorphs have been found but also to
retrospectively rationalize crystallization behaviors, polymorph
appearance, solid-state stability, and transformation pathways.
For B5 and DB7, the crystal energy landscapes certainly helped
to explain at the molecular level the diverse crystallization
behavior observed for these two molecules. This type of
information is invaluable for attaining process understanding
and has surely brought a sense of closure to the solid form
survey. However, having a crystal energy landscape available
late in development, long after solid form screening is
presumed to have delivered the ﬁnal crystal form, arguably
leaves little time to react to it, particularly when more stable
packings are calculated. In such cases, the solid form
investigations of a compound that is active in development
would inevitably be reopened to ﬁnd them and, if successful,
could prompt a switch to a more stable form. Needless to say,
late form changes are almost never welcome, requiring
crystallization and formulation processes to be reworked and
the bioequivalence of the new form to ultimately be
demonstrated, all of which invariably add considerable delays
to development timelines and increase cost.
We have found that having the crystal energy landscape
available during the solid form screening process can be very
advantageous, with the combined disciplines helping to clarify
the experimental solid form landscape and suggest new
experiments and calculations to be explored. For DB7 Form
III, a disordered structure based on two closely related packing
arrangements on the crystal energy landscape was proposed to
account for the peak splitting observed by solid-state 13C NMR
spectroscopy (Figure 15) and in so doing rule out the
possibility of a concomitantly crystallized fourth polymorphic
form being present as a phase impurity. Having a clearly
predicted potential polymorph and its structure, on the other
hand, may suggest a speciﬁc route to ﬁnd it, such as isomorphic
seeding as demonstrated for catemeric carbamazepine form V83
and phenobarbital polymorphs,84 or more general approaches,
such as crystallization under pressure,85 to ﬁnd denser forms.
Although the crystal energy landscapes of B5 and DB7 did not
suggest a worthwhile target structure, further research in
developing such strategies will undoubtedly have industrial
application. Given the strong preference to identify and lock in
the solid-state form as early as possible in drug development,
CSP needs to be applied to drug candidates in real time, that is,
concurrently with experimental solid form screening. Thus,
better algorithms and advances in computer power will be
required to improve the computational speed.
CSP methods have yet to evolve to the point where a full
solid form landscape comprising Z′ > 1 neat forms, solvates,
salts, and cocrystals could collectively be entertained, let alone
routinely explored for molecules of typical pharmaceutical
complexity. Still, with approximately 50% of pharmaceuticals
having been reported to exhibit polymorphism,86 studies like
this show how combining experimental and in silico solid form
screening to explore the solid form landscape of neat
polymorphs alone could help to right-size the experimental
search for relevant crystal forms. In cases where there simply
are not many competitive polymorphs or the forms appear
early or with relatively minimal eﬀort, experimental solid form
screening will almost always extend well beyond the point of
diminishing returns before the screens are conﬁdently judged as
complete. Having assurance from the crystal energy landscape
that all practically important polymorphs have been found,
experimental screening eﬀorts could be redirected to speciﬁcally
ﬁnding other equally important forms, including hydrates and
solvates. With B5 and DB7, however, we are reminded of the
danger in reading too much into even a reasonable
approximation of the crystal energy landscape early on, as
predicted structures may be signiﬁcantly reranked with
diﬀerent, equally well-justiﬁed approximations to the relative
energies (Figure 17).87 The uncertainty in the energy
calculations, coupled with the ability to trap kinetic forms, for
example, by desolvation, means that experimentally accessible
forms could be among the high energy structures in the crystal
energy landscape. Such was the case for DB7 Form III. Thus,
before we can truly beneﬁt from CSP studies, we need more
studies like this one, contrasting the structural relationships of
the computed crystal energy landscape with the structures and
transformations found with industrial standard screenings, to
gain conﬁdence in their interpretation in terms of polymorphs,
solvates, and disorder through to amorphous phase formation.
5. CONCLUSIONS
Two closely related piperazinyl-dimethylpropanoic acids, B5
and DB7, diﬀer markedly in their solid form landscape, with
only one crystal structure of neutral B5 being found, whereas
DB7 formed solvates (hydrates) and an amorphous form which
allowed more extensive screening. The structures of B5 Form I
and DB7 Forms I and II were solved by single crystal
diﬀraction, and a disordered structure for DB7 Form III was
proposed by combining powder diﬀraction, SSNMR, and
structures on the calculated crystal energy landscape. From the
complementary use of computational and experimental screen-
ing data, it appears that hydrogen bonding is not the dominant
driving force for the self-assembly of these molecules, and the
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diﬀerences in the favorable packing ability of the benzoisox-
azolepiperazinyl and dibenzoxepinylpiperazinyl fragments
account for the diﬀerent propensity toward solid forms.
Further developments in our ability to calculate the relative
stability of crystal structures of pharmaceutical molecules, such
as DB7 and B5, where conformational ﬂexibility and functional
group diversity produce a range of favorable structures, are
required but are a challenge to computational chemistry
modeling. However, CSP methods have advanced to a stage
of complementing solid form screening in helping bring
together the experimental observations and focus further
experimentation by providing a sense of the range of alternative
structures that are thermodynamically competitive.
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